MedTrace Logo

Probiotics for Birch Pollen Allergy

NCT00746226 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2008-09-03

No results posted yet for this study

Summary

Birch pollen allergy is one of the most common forms of respiratory allergy in the Nordic countries. Treatment consists of antihistamine use. Specific probiotic strains have been observed to modulate the immune system. Since the body has a common mucosal immune system; it was hypothesised that consumption of probiotics may affect also the respiratory mucosal immune response and hence affect respiratory allergy.

Earlier studies with probiotics had been unable to show improvements in adults with pollen allergy. It was therefore hypothesised that children, who's immune system is not yet fully developed, might be better targets.

Conditions

  • Rhinitis, Allergic, Seasonal

Interventions

BIOLOGICAL

Lactobacillus acidophilus and Bifidobacterium lactis

Daily 5x10\^9 CFU of a combination of L. acidophilus and B. lactis

BIOLOGICAL

Placebo

Microcrystalline cellulose As capsule which could be opened

Sponsors & Collaborators

  • Danisco

    lead INDUSTRY

Principal Investigators

  • Arthur C Ouwehand, PhD · Danisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2006-06-30
Completion
2007-02-28

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00746226 on ClinicalTrials.gov